View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
Profil d'Innocuité du Baricitinib Pour le Traitement de la Polyarthrite Rhumatoïde sur une Période Médiane de 3 ans de Traitement : Une Analyse d'Innocuité Intégrée Mise À Jour
Lancet Rheumatol 2020;2:e347–57RA is a chronic, life-long disease requiring long-term treatment. As such, it is important to understand the long-term safety profile of DMARDs. In this analysis, baricitinib maintained a stable safety profile during long-term exposure. This baricitinib safety analysis included integrated data from nine Phase 3, 2, and 1b clinical trials, and one long-term extension, with data up to 360 weeks. 3700 patients were included, with maximum follow-up of almost 7 years – representing an additional 3,54...